Market Closed -
Nasdaq
16:00:00 2024-06-28 EDT
5-day change
1st Jan Change
0.4987
USD
-13.81%
-16.76%
-77.23%
Presentation Operator MessageOperator (Operator)Good day, and welcome to the Aethlon Medical F...
Aethlon Medical, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024
06-27
CI
Transcript : Aethlon Medical, Inc., 2024 Earnings Call, Jun 27, 2024
06-27
HC Wainwright Adjusts Aethlon Medical Price Target to $7 From $10, Maintains Buy Rating
06-24
MT
Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier® Cancer Trial
06-18
CI
Aethlon Medical, Inc. Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies
06-03
CI
Top Midday Decliners
05-15
MT
Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures
05-13
MT
Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday
05-13
MT
Aethlon Medical, Inc. Reports Positive Results from an In Vitro Binding Study of Its Hemopurifier in Removing Extracellular Vesicles from Cancer Patient Plasma
05-10
CI
Aethlon Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
02-14
CI
Transcript : Aethlon Medical, Inc., Q3 2024 Earnings Call, Feb 14, 2024
02-14
Transcript : Aethlon Medical, Inc., Q2 2024 Earnings Call, Nov 14, 2023
11-14
Aethlon Medical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
11-14
CI
Aethlon Medical, Inc Announces Executive Changes
11-13
CI
Aethlon Medical, Inc. Announces Appointment Ofguy Ciprian as Chief Operating Officer
11-13
CI
HC Wainwright Adjusts Price Target on Aethlon Medical to $23 From $90, Maintains Buy Rating
23-10-24
MT
Aethlon Medical, Inc. Receives Clearance from Drug Controller General of India for Potential Phase 1 Trial of its Hemopurifier(R) in Oncology
23-10-10
CI
Aethlon Medical Board Approves 1-for-10 Reverse Stock Split
23-10-04
MT
Transcript : Aethlon Medical, Inc., Q1 2024 Earnings Call, Aug 10, 2023
23-08-10
Aethlon Medical, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023
23-08-10
CI
Aethlon Medical, Inc. Appoints Nicolas Gikakis as Member of the Board and Member of the Nominating Committee
23-07-06
CI
Transcript : Aethlon Medical, Inc., Q4 2023 Earnings Call, Jun 28, 2023
23-06-28
Aethlon Medical, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023
23-06-28
CI
Transcript : Aethlon Medical, Inc., Q3 2023 Earnings Call, Feb 13, 2023
23-02-13
Aethlon Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
23-02-13
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. The Hemopurifier, in pre-clinical studies, has demonstrated the removal of harmful exosomes from biological fluids, utilizing its lectin-based technology. The Hemopurifier is a United States Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption application related to the treatment of life-threatening viruses that are not addressed with approved therapies.
More about the company
Last Close Price
0.4987
USD
Average target price
7
USD
Spread / Average Target
+1,303.65%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1